Stephen K L Chia

11PUBLICATIONS
64CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursPredictive and prognostic markersMolecular targetsTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Mar 19, 2026
Correction to: A Canadian real‑world, multi‑center, prospective, observational study assessing the treatment duration, the treatment sequence, and the overall survival for patients treated with endocrine therapy ± targeted therapy in HR + HER2‑negative advanced breast cancer.

Catherine Doyle, Ana Elisa Lohmann, Nayyer Iqbal

|Aug 29, 2025
Matching-adjusted indirect comparison of ribociclib + nonsteroidal aromatase inhibitor versus abemaciclib + endocrine therapy in hormone receptor-positive/HER2-negative early breast cancer.

Stephen Chia, Jie Li, Fei Ma

|Feb 28, 2025
Health-Related Quality of Life in Patients with HR+/HER2- Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE Trial.

Peter A Fasching, Dennis Slamon, Zbigniew Nowecki

|Jan 23, 2025
A Canadian real-world, multi-center, prospective, observational study assessing the treatment duration, the treatment sequence, and the overall survival for patients treated with endocrine therapy ± targeted therapy in HR + HER2-negative advanced breast cancer.

Catherine Doyle, Ana Elisa Lohmann, Nayyer Iqbal

|Dec 05, 2024
Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors.

Tharani Krishnan, Joao Paulo Solar Vasconcelos, Emma Titmuss

|Jul 24, 2024
Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial.

Priya Rastogi, Hanna Bandos, Peter C Lucas

Pageof 2

Frequent Collaborators

2 joint publications

Charles E Geyer

2 joint publications

Norman Wolmark

2 joint publications

Janice M Walshe

2 joint publications

Louis Fehrenbacher